Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy
For SARS-CoV-2 mutants, the effectiveness of the COVID-19 vaccines is still controversial. In this study, we aimed to investigate the clinical characteristics of Omicron-infected patients who completed primary immunization and booster immunization, respectively, during the rapid propagation of the O...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/5/968 |
| _version_ | 1797598179413196800 |
|---|---|
| author | Yingyu He Fang Zhang Yan Liu Zhou Xiong Shangen Zheng Wanbing Liu Lei Liu |
| author_facet | Yingyu He Fang Zhang Yan Liu Zhou Xiong Shangen Zheng Wanbing Liu Lei Liu |
| author_sort | Yingyu He |
| collection | DOAJ |
| description | For SARS-CoV-2 mutants, the effectiveness of the COVID-19 vaccines is still controversial. In this study, we aimed to investigate the clinical characteristics of Omicron-infected patients who completed primary immunization and booster immunization, respectively, during the rapid propagation of the Omicron variant in China. A total of 932 patients with confirmed SARS-CoV-2 infection from 18 December 2022 to 1 January 2023 were included in this survey by filling out questionnaires online. The enrolled patients were divided into the primary immunization group and the booster immunization group according to their vaccination status. During the whole course of disease, the most frequent symptoms were fever (90.6%), cough (84.3%), weakness (77.4%), headache and dizziness (76.1%), and myalgia (73.9%). Nearly 90% of the patients had symptoms lasting for less than 10 days, and 39.8% of the patients ended the course of the disease in 4–6 days. A total of 58.8% of these patients had a fever with a maximum body temperature of over 38.5 °C. Moreover, 61.4% of the patients had a fever that lasted less than 2 days. There were no obvious differences in initial symptoms, cardinal symptoms, symptom duration time, maximum body temperature, and fever duration time between the two groups of patients. In addition, no significant difference was found in the positive or negative conversion time of SARS-CoV-2 antigen/nucleic acid between the two groups of patients. For mild patients with Omicron breakthrough infection, enhanced immunization has no significant impact on the clinical performance and duration of viral infection compared with primary immunization. The reasons behind the different clinical manifestations of patients with mild symptoms after the breakthrough infection of the Omicron strain are still worth further research. Heterologous vaccination may be a better strategy for enhanced immunization, which can help improve the immune protection ability of the population. Further research should be carried out on vaccines against mutant strains and spectral anti-COVID-19 vaccines. |
| first_indexed | 2024-03-11T03:15:43Z |
| format | Article |
| id | doaj.art-b8220515eb1a4a0b8c83655b3fd703c6 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T03:15:43Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-b8220515eb1a4a0b8c83655b3fd703c62023-11-18T03:36:27ZengMDPI AGVaccines2076-393X2023-05-0111596810.3390/vaccines11050968Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 PolicyYingyu He0Fang Zhang1Yan Liu2Zhou Xiong3Shangen Zheng4Wanbing Liu5Lei Liu6Hubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan 430070, ChinaDepartment of Anesthesiology, General Hospital of Central Theater Command of the PLA, Wuhan 430070, ChinaDepartment of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan 430070, ChinaDepartment of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan 430070, ChinaDepartment of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan 430070, ChinaHubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan 430070, ChinaHubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan 430070, ChinaFor SARS-CoV-2 mutants, the effectiveness of the COVID-19 vaccines is still controversial. In this study, we aimed to investigate the clinical characteristics of Omicron-infected patients who completed primary immunization and booster immunization, respectively, during the rapid propagation of the Omicron variant in China. A total of 932 patients with confirmed SARS-CoV-2 infection from 18 December 2022 to 1 January 2023 were included in this survey by filling out questionnaires online. The enrolled patients were divided into the primary immunization group and the booster immunization group according to their vaccination status. During the whole course of disease, the most frequent symptoms were fever (90.6%), cough (84.3%), weakness (77.4%), headache and dizziness (76.1%), and myalgia (73.9%). Nearly 90% of the patients had symptoms lasting for less than 10 days, and 39.8% of the patients ended the course of the disease in 4–6 days. A total of 58.8% of these patients had a fever with a maximum body temperature of over 38.5 °C. Moreover, 61.4% of the patients had a fever that lasted less than 2 days. There were no obvious differences in initial symptoms, cardinal symptoms, symptom duration time, maximum body temperature, and fever duration time between the two groups of patients. In addition, no significant difference was found in the positive or negative conversion time of SARS-CoV-2 antigen/nucleic acid between the two groups of patients. For mild patients with Omicron breakthrough infection, enhanced immunization has no significant impact on the clinical performance and duration of viral infection compared with primary immunization. The reasons behind the different clinical manifestations of patients with mild symptoms after the breakthrough infection of the Omicron strain are still worth further research. Heterologous vaccination may be a better strategy for enhanced immunization, which can help improve the immune protection ability of the population. Further research should be carried out on vaccines against mutant strains and spectral anti-COVID-19 vaccines.https://www.mdpi.com/2076-393X/11/5/968COVID-19omicronbreakthrough infectionbooster vaccinationprimary vaccination |
| spellingShingle | Yingyu He Fang Zhang Yan Liu Zhou Xiong Shangen Zheng Wanbing Liu Lei Liu Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy Vaccines COVID-19 omicron breakthrough infection booster vaccination primary vaccination |
| title | Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy |
| title_full | Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy |
| title_fullStr | Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy |
| title_full_unstemmed | Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy |
| title_short | Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy |
| title_sort | clinical characteristics of mild patients with breakthrough infection of omicron variant in china after relaxing the dynamic zero covid 19 policy |
| topic | COVID-19 omicron breakthrough infection booster vaccination primary vaccination |
| url | https://www.mdpi.com/2076-393X/11/5/968 |
| work_keys_str_mv | AT yingyuhe clinicalcharacteristicsofmildpatientswithbreakthroughinfectionofomicronvariantinchinaafterrelaxingthedynamiczerocovid19policy AT fangzhang clinicalcharacteristicsofmildpatientswithbreakthroughinfectionofomicronvariantinchinaafterrelaxingthedynamiczerocovid19policy AT yanliu clinicalcharacteristicsofmildpatientswithbreakthroughinfectionofomicronvariantinchinaafterrelaxingthedynamiczerocovid19policy AT zhouxiong clinicalcharacteristicsofmildpatientswithbreakthroughinfectionofomicronvariantinchinaafterrelaxingthedynamiczerocovid19policy AT shangenzheng clinicalcharacteristicsofmildpatientswithbreakthroughinfectionofomicronvariantinchinaafterrelaxingthedynamiczerocovid19policy AT wanbingliu clinicalcharacteristicsofmildpatientswithbreakthroughinfectionofomicronvariantinchinaafterrelaxingthedynamiczerocovid19policy AT leiliu clinicalcharacteristicsofmildpatientswithbreakthroughinfectionofomicronvariantinchinaafterrelaxingthedynamiczerocovid19policy |